According to our recent payer coverage analysis for bipolar disorder treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A review of market access for bipolar disorder treatments shows that under the pharmacy benefit, about 21% of the lives under commercial formularies are covered with utilization management restrictions.
Trends: In May 2021, the FDA approved Alkermes plc’s Lybalvi (olanzapine and samidorphan) for adults with schizophrenia and for adults with bipolar I disorder, for the acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate and as a maintenance monotherapy treatment.